Gossamer Bio Reports Q2 2026 Financial Results (Press Release)

What Happened

• Gossamer Bio, Inc. (GOSS) filed a Current Report on Form 8‑K on August 13, 2026 (Items 2.02 and 9.01) to furnish a press release announcing its financial results for the quarter ended June 30, 2026. The full press release is attached as Exhibit 99.1 to the filing. The company notes the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated.

Key Details

• Press release reporting quarterly results issued August 13, 2026 and covers the quarter ended June 30, 2026.
• The press release is attached to the Form 8‑K as Exhibit 99.1.
• Inline XBRL cover page data file included as Exhibit 104.
• Form 8‑K is signed by Bryan Giraudo, Chief Financial Officer and Chief Operating Officer, dated August 13, 2026.

Why It Matters

• This filing notifies investors that Gossamer has released its latest quarterly financial and operational results (earnings information), which may include revenue, expenses, cash position and business updates in the attached press release.
• Because the company furnished — rather than “filed” — the press release under General Instruction B.2, the content is for investor information but carries different legal treatment regarding Section 18 liabilities and incorporation by reference.
• Investors should read the attached Exhibit 99.1 press release (and any subsequent filings) for the detailed figures and company commentary on quarterly performance and outlook.